A&G Pharmaceutical Receives 2009 Maryland Business Incubator Award
News Jun 22, 2009
A&G Pharmaceutical received the “Best Graduate Company” Award at the 2009 Maryland Incubator of the Year Awards on June 16, 2009.
The award was presented in recognition of the company’s diagnostic products in development based on a biological target, or biomarker, discovered by A&G researchers known as GP88/PGRN, which plays a critical role in helping the cancer to grow and proliferate.
A&G initiated operations in 2000 in the Emerging Technology Center incubator in Baltimore to develop and commercialize linked therapeutic-diagnostic products for personalized medicine based on its biomarker discoveries, with a focus on cancer.
The company, which now has 22 employees, has two diagnostic tests for breast cancer in clinical trials, a linked breast cancer therapeutic in development, and additional longer-term diagnostic products in development for lung cancer and prostate cancer.
“We are very pleased that the Maryland business community has bestowed the honor of Best Graduate Company on A&G,” said Ginette Serrero, PhD, Chief Executive Officer of A&G. “We could not accept this award without acknowledging Ann Lansinger, President of the Emerging Technology Centers, who provided the critical assistance at A&G’s inception that enabled us to incubate.
Source of a Potent Greenhouse Gas IdentifiedNews
A study of a Lake Erie wetland suggests that scientists have vastly underestimated the number of places methane-producing microbes can survive—and, as a result, today’s global climate models may be misjudging the amount of methane being released into the atmosphere.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE